BRCA1 and cancer: Importantly, homozygous deletions of factors identified as synthetic lethal with EXO1 loss in this study are found in 8.49% of all cancers (Table 1), defining a significant proportion of cancers potentially targetable by EXO1 inactivation, which is in addition to the previously identified population of BRCA1-deficient cancers33.